Monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma, is one of the most common premalignant conditions in the general population. The etiology of MGUS is largely unknown.
Introduction
Monoclonal gammopathy of undetermined significance (MGUS) is one of the most common premalignant plasma cell disorders. It is a precursor for multiple myeloma (MM) and other related plasma cell malignancies. MGUS is defined by a serum monoclonal (M) protein level of less than 3 grams per deciliter, less than 10% of clonal plasma cells in the bone marrow, and absence of clinical CRAB (hypercalcemia, renal insufficiency, anemia, and/or bone lesions) characteristics that can be attributable to a plasma cell proliferative disorder. 1 Approximately 3% of the general population aged 50 years and older have MGUS. 2 The prevalence increases with age, ranging from 1.7% in those 50-59 years of age, to greater than 5% in those older than 70. 2 The rate of progression of MGUS to malignancy is approximately 1% per year. 2 MGUS is more prevalent in men (4.0% over age 50) than in women (2.7% over age 50). 2 Differences in prevalence have also been seen across racial and ethnic groups. For example, reports indicate that individuals of Asian descent have a lower prevalence of MGUS compared with their white counterparts. 3 Additionally, those of African and African-American descent have been reported to have approximately a two-to three-fold increased prevalence compared with white populations. 4, 5 These differential rates of MGUS by race suggest possible differences in environmental and/or genetic risk factors for MGUS.
For personal use only. on October 24, 2017 . by guest www.bloodjournal.org From A few studies have indicated that there is an increased prevalence of MM among blood relatives of probands with MM. 6, 7 From recent data, there also appears to be an increased prevalence of MGUS in families containing at least one individual with a lymphoid or plasma cell proliferative disorder. 8 Investigations have been performed to estimate the magnitude of the excess risk in first-degree relatives and explore possible underlying mechanisms. 9 The purpose of this review is to summarize the current literature on familial MGUS and MM and discuss future directions for research.
Epidemiology of familial MGUS and MM
The majority of studies of familial MGUS and MM have been case studies of a collection of families with multiple cases of MGUS, MM, and other hematologic malignancies. Furthermore, most of these investigations have been conducted in white populations. One of these earliest studies to examine familial aggregation of MGUS and MM described one family in which two siblings were diagnosed with MGUS. 10 Upon further investigation, it was found that a total of five of the seven siblings had a monoclonal gammopathy (four cases of MGUS and one case of MM). Another study described eight families with two probands with a monoclonal gammopathy (with MGUS, MM, or Waldenstrom's macroglobulinemia (WM)). 11 Relatives were traced back two generations prior to the proband; additionally, any individual from a younger generation over the age of twenty was included, yielding 4370 family members total. Linkage of these No significant differences were reported regarding which relative was examined (parent, offspring, and sibling).
In a previously discussed Swedish population-based study of family members of 4,458 MGUS probands, increased prevalence of other lymphoproliferative conditions in addition to MM and MGUS were identified. 8 Taken together, our review of the literature suggests that besides myeloma and related disorders, first-degree relatives of persons with monoclonal gammopathies have a two-to four-fold increase in the risk of certain lymphoproliferative disorders such as LPL/WM and CLL, and that this risk depends on the type of the M protein in the proband. In contrast there appears to be a smaller and, in our opinion not a clinically significant increase in the risk of other cancers.
Genetics and biological mechanisms of familial MGUS and other monoclonal gammopathies

Genome-wide linkage analysis
There have been few studies to date investigating genetic influence on MGUS. One genome-wide linkage analysis has been conducted on 11 families of probands with WM. Of the 122 family members included in the study, 10 were confirmed cases of IgM MGUS and an additional 34 had WM. 17 Investigators genotyped and analyzed 1,058 microsatellite markers using both parametric and nonparametric methods. In an analysis in which those with MGUS and WM were labeled as "affected," linkage was found on chromosomes 1q and 4q. The nonparametric linkage scores reported were 2.5 for 1q and 3.1 for 4q (p = 0.0089 and 0.004, respectively). The authors propose that this information could be useful in identifying genes that function as susceptibility factors for both conditions. However, these data are preliminary, and no genes for either WM or MGUS have been identified in these regions to date. and were found to have hyperphosphorylated P-7. Examination of inheritance in the four families tested also found hyperphosphorylated P-7 to be a dominantly inherited trait.
Biological factors underlying familial MGUS
A final study was conducted in order to assess the prevalence of hyperphosphorylated P-7 within families with a history of MGUS/MM. 21 Using 31
unaffected and 10 individuals with MGUS/MM from four families, Grass et al.
determined that hyperphosphorylated P-7 was a target for the paratag proteins of two affected family members. Additionally, it was found that paratag protein-8 (P-8) was an antigenic target from 4 affected members of one family; this paraprotein was also hyperphosphorylated and inherited in a dominant fashion.
Additional hyperphosphorylated nonfamilial paratag proteins were found in affected individuals, leading to the conclusion that hyperphosphorylation of paratag proteins may underlie the pathogenesis of MGUS and/or MM, and that hyperphosphorylated P-7 and P-8 specifically may be more prevalent in familial MGUS/MM.
The above studies are limited by the fact that they do not systematically compare the prevalence of hyperphosphorylated P-7 (or P-8) in sporadic versus familial MGUS in well-defined cohorts. Thus while interesting and hypothesisgenerating, additional confirmatory evidence and mechanistic studies are needed.
For
Hyper-responsive B-cells
One of the proposed phenotypes that may underlie familial MGUS is the hyper-responsive B-cell phenotype, seen when pokeweed mitogen is applied in vitro, causing increased production of IgA, IgG, and IgM. Individuals from eight families with multiple cases of either MGUS or MM were examined for this phenotype using blood samples cultured and stimulated by pokeweed mitogen.
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One unaffected control was chosen for each of the cases and was matched on age and sex. Of the 62 healthy family members, 7 were IgG hyper-responders; four were IgM hyper-responders; and one individual was hyper-responsive with increased production of both IgG and IgM. Eight of these hyper-responders were from one family, two came from another family, and the final two were each from a unique family. Additionally, 10 individuals had increased production of antibody production, but not enough to be classified as hyper-responders. Among the controls, only two were classified as hyper-responders. These results suggest that hyper-responsive B-cells could be a potential novel endophenotype for familial monoclonal gammopathies. They are of particular interest since they provide a rational mechanistic basis for the generation of monoclonal plasma cell populations in close family members who share an inherited hyper-responsive B cell phenotype.
Familial multiple myeloma and other cancers
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Aggregation of multiple myeloma in families
Interest in examining familial MGUS arose partly from findings of familial aggregation in MM and other blood cancers. In a review of the literature documenting siblings with plasma cell disorders and monoclonal gammopathies prior to 1985, of the 38 pairs of affected siblings reported, eight families had an additional sibling affected and 4 had a fourth affected relative. 22 Additional reports since the 1980s have reported several cases of MM in siblings as well as in parents and children. [23] [24] [25] [26] The above studies demonstrated the presence of familial clustering in myeloma, and laid the foundation for subsequent confirmatory studies. Of note, patterns of MM and other hematologic malignancies have been found anecdotally in spouses, suggestive of environmental influences.
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A retrospective study of 104 Intergroupe Francophone du Myelome centers examined the incidence of MM in siblings of MM patients as well as other close relatives. 28 Of the participating centers, 14 reported 15 cases of familial MM. Of these, ten cases involved siblings, four involved parents and children, and one involved an aunt and nephew. It was also noted that among these families, there were also three cases of MGUS. A subsequent study of the Swedish Family Cancer Database, found a clear increase in the incidence of MM in offspring of individuals with a previous diagnosis of MM (SIR = 3.33, 95% CI, 2.11 to 5.00). 29 Overall, several family studies have documented aggregation of MM in first-degree blood-relatives (Table 1) . 7, 12, 30, 31 It is important to note that a limitation of some of these studies is the lack of comparison group. Together, though, these studies imply an increased risk of MM exists in first-degree relatives of patients with MM. In concert with the epidemiologic and biologic studies of familial MGUS they suggest that this increased risk is likely the result of inherited genetic susceptibility factors.
Given the increased risk of developing multiple myeloma in persons of 35 Data revealed almost a two-fold increased risk for first-degree female relatives of MM probands for a grouping of hematologic malignancies (ICD-10 codes C81-C96) (RR = 1.95, 95%CI, 1.1 to 3.2). From the 218 MM probands, eight families were identified in which the proband had more than one relative with MGUS and more than one with another hematologic malignancy; in four of these families, another relative had MM, and in three, both myeloid and lymphoid conditions were found. at least one relative with a prior malignancy. 37, 38 For
Some small studies have identified associations between MM probands and certain solid tissue tumors in first-degree blood-relatives. 12, 39 More recently, these findings were validated in a study conducted by Kristinsson and colleagues using Swedish population-based data and family linkage. 40 Risks for hematologic malignancies and solid tumors, as well as MGUS, were assessed for first-degree blood-relatives of 13,896 MM probands (37,838 relatives) and 54,365 matched controls (151,068 relatives). Family members of MM probands were at a small but increased risk for developing any solid tumor (RR = 1.1, 95%
CI, 1.0 to 1.1), most notably bladder cancer (RR=1.3, 95%CI, 1.0 to 1.5). In terms of hematologic malignancies, the Swedish study found that first-degree relatives had an increased risk of MM (RR = 2.1, 95% CI, 1.6 to 2.9), MGUS (RR=2.1, 95% CI, 1.5 to 3.1), and acute lymphoblastic leukemia (ALL) (RR=2.1, 95%CI, 1.0 to 4.2). Overall, the absolute excess risk for solid tumors in first degree relatives of MM patients is very small (10%) relative to the excess seen for MM, MGUS and ALL.
Despite inherent limitations of retrospective cohort and registry studies, our overall interpretation of the literature is that first degree relatives of MM patients have a two-fold higher risk of certain hematologic malignancies including MM. In contrast there appears to be a less pronounced but in our opinion not a clinically significant increase in the risk of solid tumors. 
Common Genetic Predisposition
As discussed earlier, studies suggest clustering of MGUS with CLL, LPL/WM and NHL 8, [14] [15] [16] and MM with ALL and CLL in families. [32] [33] [34] [35] [36] [37] [38] The increased risk of hematologic malignancies, in particular B-cell, in first degree relatives of both MM and MGUS probands supports a common genetic predisposition. There have recently been several genetic variants identified for CLL and other subtypes of NHL. [45] [46] [47] [48] [49] These variants as well as those yet unidentified, may also contribute to familial MGUS and MM.
Future Directions
There are several aspects of familial MGUS and MM that warrant continued investigation. First, priority needs to be placed on understanding familial aggregation of MGUS and MM in African Americans and those of African descent, especially given the elevated risk of disease in this demographic. 
